Viz.ai, a medical technology company specializing in disease diagnostics and intelligent care coordination, has received the 2024 Prix Galien USA Award for Best Digital Health Solution.
According to the company’s announcement, it received the award for its innovative Hypertrophic Cardiomyopathy module, Viz HCM™, highlighting the technology’s transformative impact on AI-powered coordinated patient care.
The Prix Galien Award, often dubbed the “Nobel Prize of life sciences,” is one of the most distinguished accolades in the field of life sciences. It recognizes exceptional innovations with great potential to transform human health and healthcare at large.
According to Dr. Chris Mansi, CEO and co-founder at Viz.ai, the company’s HCM module enhances the diagnostic journey for patients with hypertrophic cardiomyopathy by enabling faster diagnosis and delivering the appropriate follow-up care they need for optimum therapy outcomes.
The First and Only FDA-cleared AI-driven Solution
Developed by funding from Bristol Myers Squibb (BMS), Viz HCM is the first-ever AI-powered solution capable of analyzing 12-lead electrocardiograms (ECGs). It leverages an advanced AI model to identify potential HCM cases, notify care teams, and ensure the patient receives an appropriate diagnosis, treatment, and follow-up care.
Viz HCM received FDA-s De Novo approval in 2023, an authorization reserved for novel technology innovations providing unique solutions that did not exist in the market.
